Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible.

Business Wire • a day ago

AstraZeneca: This Mighty Pharma Is Undervalued Ahead Of Q3 Earnings

AstraZeneca remains a long-term Buy despite recent setbacks, underpinned by robust product and pipeline strength. AZN targets $80bn in revenues by 2030, supported by 14 current blockbusters and a pipeline potentially adding 12 more by the decade's end. Recent pipeline wins in oncology, respiratory, and immunology offset the eplontersen ATTR-CM study failure and Farxiga's US LOE.

Seeking Alpha • Oct 23, 2026

FDA Conditionally Approves AstraZeneca's Rare Kidney Disease Drug

The U.S. Food and Drug Administration (FDA) on Thursday granted accelerated approval to AstraZeneca Plc's (NYSE:AZN) Ultomiris (ravulizumab) to lower proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.

Benzinga • Oct 22, 2026

AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy

AZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.

Zacks Investment Research • Oct 22, 2026

ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, and whose disease has progressed on or after platinum-based chemotherapy.1 The US Food and Drug Administration granted accelerated approval to ZEGFROVY based on res.

Business Wire • Oct 22, 2026

AstraZeneca says FDA approves drug for rare kidney disease in adults

AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its treatment ​for adults with immunoglobulin A nephropathy, a ‌rare kidney disease that can lead to renal failure.

Reuters • Oct 21, 2026

Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss

Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.

Zacks Investment Research • Oct 21, 2026

Jefferies puts AstraZeneca kidney drug trial success odds at 59%

Jefferies, the investment bank, estimates a 59% probability that AstraZeneca PLC (LSE:AZN, NYSE:AZN)'s zibotentan succeeds in the phase 3 ZENITH-HP kidney disease trial, which is due to report in the first half of 2027. The broker rates AstraZeneca, the FTSE 100 drugmaker, a 'buy' with a price target of 17,500p, which implies 41% upside from Monday's close of 12,446p.

Proactive Investors • Oct 20, 2026

AstraZeneca Partners With Oracle to Refine Clinical Research With AI

AstraZeneca is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the pharmaceutical industry.

WSJ • Oct 20, 2026

AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial

Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved disease remission in 69% ​of patients with a type of chronic inflammatory disorder ‌of the esophagus.

Reuters • Oct 20, 2026